Laura Panjwani

Articles

Use of Radium-223 Continues to Evolve in mCRPC

November 12th 2015

Michael Morris, MD, discusses the potential of radium-223 and how the agent could be successful and impactful in metastatic castration-resistant prostate cancer.

Experts Discuss Exciting Novel Therapies, Challenges in RCC

November 11th 2015

Robert Figlin, MD, and Daniel Petrylak, MD, discuss emerging agents in RCC they are excited about and what challenges still remain in treating the disease.

Biomarkers, Novel Agents Continue to Advance Multiple Myeloma Treatment

November 11th 2015

Shaji Kumar, MD, discusses how newly approved agents and other changes have affected the treatment of multiple myeloma and what is on the horizon for the disease.

PD-1 Agents Top Choice for Second-Line NSCLC

November 9th 2015

Roman Perez-Soler, MD, expanded on the importance of PD-1 inhibitors for all patients and the role of biomarker testing.

Motzer Discusses Nivolumab's Survival, QoL Benefits in RCC

November 2nd 2015

Robert J. Motzer, MD, discusses nivolumab's impact for renal cell carcinoma treatment.

Expert Discusses Future of Immunotherapy in Lung Cancer

October 30th 2015

Heather Wakelee, MD, reflected on the evolution of lung cancer treatment and just how significant of an impact immunotherapies may have.

Petrylak Highlights Potential of PD-1/PD-L1 Inhibitors in Bladder Cancer

October 29th 2015

PD-1/PD-L1 agents have shown significant potential for the treatment of urothelial bladder cancer, Daniel Petrylak, MD, from Yale Cancer Center, noted in a recent interview with OncLive.

Sartor Discusses Expanded Radium-223 Program, STAMPEDE Data in Prostate Cancer

October 27th 2015

Oliver Sartor, MD, expands on the impact of the STAMPEDE and CHAARTED trials and discusses how the results may change the treatment paradigm for prostate cancer going forward.

Anti-CD20 Antibodies Effective in Elderly CLL Patients

October 27th 2015

Alessandra Ferrajoli, MD, discusses the impact of the CLL11 and COMPLEMENT 1 trials, as well as other treatments that may be beneficial to the elderly chronic lymphocytic leukemia population.

CLL Expert Discusses Venetoclax, Promising Next-Generation Agents

October 27th 2015

Jennifer R. Brown, MD, PhD, discusses the future of chronic lymphocytic leukemia treatment.

Radiation Underutilized in Low-Grade Follicular Lymphoma

October 22nd 2015

The use of radiation therapy has declined despite evidence demonstrating it is often more beneficial than single-agent chemotherapy or observation-alone in patients with low-grade follicular lymphoma.

Nivolumab Investigator Discusses Expanded Approval, Compares With Pembrolizumab

October 16th 2015

Dr. Ben Creelan, discusses the impact of the expanded approval of nivolumab in NSCLC and how the drug compares with pembrolizumab.

BRCA+ Patients May Have Higher Risk of Serous Uterine Cancers After RRSO

October 15th 2015

Dr. Noah Kauff discusses how hysterectomy, in addition to standard risk-reducing salpingo-oophorectomy (RRSO) measures, should be considered in BRCA+women to reduce the risk of serous uterine cancers.

TILs Emerge as Robust Biomarker, Shed Light on Immunotherapy Potential in TNBC

October 14th 2015

Sylvia Adams, MD, explains the potential of TILs, as well as other biomarkers, including PD-1/PD-L1, in TNBC and other breast cancer types.

The Limitations of VEGF Inhibition in Colorectal Cancer

October 14th 2015

Leonard Saltz, MD, discusses antiangiogenesis and the use of VEGF inhibitors in colorectal cancer.

Ten Years After Sorafenib, TKIs Are Still Advancing Kidney Cancer Treatment

October 13th 2015

Robert Figlin, MD, discusses the evolution of TKIs in renal cell carcinoma, the novel agents and changes to established therapies he is most excited about, and the challenges that still remain.

Adjuvant HER2+ Breast Cancer Care Evolves, But Questions Remain

October 9th 2015

Mohammad Jahanzeb, MD, discusses therapeutic agents that may fit into the adjuvant setting treatment paradigm for HER2-positive breast cancer, the increasing importance of genomic testing, and individualized treatments as multiple agents emerge.

Demetri Interprets Survival Outcomes for Trabectedin in Soft Tissue Sarcomas

October 8th 2015

George D. Demetri, MD, expands on the challenges with overall survival as a primary outcome measure, the potential of trabectedin in soft tissue sarcomas, and the significance of a recent trial.

PD-L1 Inhibitor Avelumab May Improve Survival in Metastatic Urothelial Carcinoma

October 7th 2015

Andrea B. Apolo, MD, explains the challenges that still remain regarding toxicity and future combination therapies with avelumab, and the potential of checkpoint inhibition in urothelial carcinoma going forward.

Checkpoint Inhibition Continues Rapid Advance in Non-Small Cell Lung Cancer

October 6th 2015

Naiyer A. Rizvi, MD, discusses the future outlook for PD-1/PD-L1 checkpoint agents in non-small cell lung cancer and the potential for immunotherapy combinations.